Is BioGaia (OM:BIOG B) Undervalued Following Strong Q2 Earnings?
Why BioGaia Stock Is In Focus After Q2 Earnings
BioGaia (OM:BIOG B) is drawing attention after reporting second quarter 2026 results, with sales of SEK 440.86 million and net income of SEK 103.16 million, both above the figures reported a year earlier.
For the first six months of 2026, BioGaia reported sales of SEK 813.41 million and net income of SEK 182.57 million, alongside basic earnings per share from continuing operations of SEK 1.8, compared with SEK 1.66 in the same period last year.
See our latest analysis for BioGaia.
BioGaia’s SEK124.8 share price has reacted strongly to the earnings release, with a 1-day share price return of 7.59% and year to date share price return of 18.86%, while the 1-year total shareholder return of 29% points to steadily building momentum.
If strong recent performance has you thinking about what else is moving, this is a good moment to broaden your watchlist with 108 top founder-led companies
After a 7.59% jump in a single session and a 29% 1 year total return, BioGaia is no longer an overlooked probiotic specialist. Does that recent strength justify paying up now, or does it make more sense to wait for a cooler entry, as the valuation section shows?
Most Popular Narrative: 24% Undervalued
Compared with BioGaia’s last close at SEK124.8, the most followed narrative points to a fair value of SEK165, implying meaningful upside based on its long term earnings profile.
BioGaia's strategic shift to direct sales in new and existing markets (e.g., Netherlands, France, Australia, U.S.) leverages rising consumer demand for natural and clinically-proven solutions. This is described as paving the way for improved operating leverage and long-term margin expansion as direct business now represents 36% of sales and continues to grow.
Want to see what sits behind that confidence in BioGaia’s direct sales push? The narrative leans heavily on future revenue mix, margin uplift and richer earnings power.
Result: Fair Value of SEK165 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the BioGaia story still carries clear risks, including rising operating expenses and pressure on cash flow that could limit future spending flexibility.
Find out about the key risks to this BioGaia narrative.
Another View On BioGaia’s Valuation
The fair value of SEK165 from the earnings based narrative paints BioGaia as undervalued, but the current P/E of 36.4x complicates the picture. It is above the European Biotechs average of 16.1x and slightly above the fair ratio of 34x, which suggests some valuation risk if sentiment cools.
With peers on 107.6x, BioGaia still looks cheaper than many direct comparables, so the question is whether you focus more on the sector wide premium or the gap to that lower fair ratio when judging upside versus downside.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Balanced on both risks and rewards, does BioGaia’s recent momentum match your own conviction? To weigh the trade off yourself, take a closer look at the 3 key rewards and 1 important warning sign
Looking For More Investment Ideas Beyond BioGaia?
If BioGaia has your attention, do not stop there. Broaden your opportunity set by checking other focused stock ideas sourced from the Simply Wall Street Screener.
- Target higher potential upside by scanning a curated list of underpriced companies through the 238 high quality undervalued stocks.
- Strengthen portfolio resilience by focusing on companies that pair reasonable valuations with solid finances using the solid balance sheet and fundamentals stocks screener (419 results).
- Hunt for overlooked opportunities with quality fundamentals before the crowd catches on by reviewing the screener containing 510 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com